| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | 74.4 | ¤1,001,823 | US |
| JNJ | Johnson & Johnson | 64.9 | ¤491,256 | US |
| MRK | Merck & Co., Inc. | 68.0 | ¤242,642 | US |
| ABT | Abbott Laboratories | 59.6 | ¤222,767 | US |
| TMO | Thermo Fisher Scientific Inc. | 49.6 | ¤220,721 | US |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| ZBH | Zimmer Biomet Holdings, Inc. | 45.0 | ¤18,268 | US |
| DGX | Quest Diagnostics Incorporated | 52.8 | ¤21,275 | US |
| LH | Labcorp Holdings Inc. | 47.6 | ¤22,022 | US |
| PODD | Insulet Corporation | 61.5 | ¤23,297 | US |
| DXCM | DexCom, Inc. | 68.7 | ¤23,491 | US |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc. | 68.1 | 31 | US |
| LLY | Eli Lilly and Company | 74.4 | 26 | US |
| PFE | Pfizer Inc. | 56.1 | 24 | US |
| DGX | Quest Diagnostics Incorporated | 52.8 | 22 | US |
| ZTS | Zoetis, Inc. Class A | 61.0 | 22 | US |
| BMY | Bristol-Myers Squibb Company | 64.1 | 21 | US |
| JNJ | Johnson & Johnson | 64.9 | 21 | US |
| TMO | Thermo Fisher Scientific Inc. | 49.6 | 21 | US |
| RMD | ResMed Inc. | 69.4 | 19 | US |
| GILD | Gilead Sciences, Inc. | 68.4 | 18 | US |
| Average Market Cap | ¤138,647 |
| Median Market Cap | ¤79,444 |
| Avg. 3 Mo. Dollar Vol. | ¤682,218,242 |
| Avg. 3 Mo. Trading Vol. | 5,833,615 |
| Last Rebalance Date | 09/22/2025 |
| Companies Replaced | 10 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 26.1 |
| Forward P/E Ratio (12 Mo.) | 18.6 |
| Price/Book Ratio | 6.0 |
| Avg. Revenue Chg. - 3 Yr | 12.5% |
| Avg. Op. Income Chg. - 3 Yr. | 19.8% |
| Avg. EPS Growth - 3 Yr. | 8.0% |
| Avg. EPS Growth - 1 Yr. | 10.8% |
| Avg. Operating Margin | 18.8% |
| Avg. LT Debt to Total Capital | 41.6% |
| Avg. Return on Equity | 19.7% |
| Dividend Yield | 0.9% |
| US Health Care Index | 60.19 |
| United States Of America | 90.0% |
| Ireland | 6.67% |
| Switzerland | 3.33% |
